drugset / Trial / NCT00151749

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

NCT00151749

Phase 3 Completed 260 enrolled Daiichi Sankyo
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to see how safe and effective and tolerable the use of WelChol® is for type 2 diabetes when added to insulin alone or in combination with other anti-diabetic drugs

Timeline

Start
2004-06
Primary completion
2005-12
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Colesevelam Other / unclassified 3.75 g